These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8527710)

  • 41. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study.
    Vogel W; Graziadei I; Umlauft F; Datz C; Hackl F; Allinger S; Grünewald K; Patsch J
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):81S-85S. PubMed ID: 9011481
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Ursodeoxycholic hemisuccinate in the treatment of chronic active hepatitis. A controlled clinico-therapeutic study].
    Buzzelli G; Moscarella S; Focardi G; Dattolo P; Giusti A; Calviani L; Relli P; Gentilini P
    Minerva Med; 1992 Sep; 83(9):537-40. PubMed ID: 1436604
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-alpha therapy in Japanese patients with chronic hepatitis C.
    Orito E; Mizokami M; Nakano T; Terashima H; Nojiri O; Sakakibara K; Mizuno M; Ogino M; Nakamura M; Matsumoto Y
    J Med Virol; 1994 Dec; 44(4):410-4. PubMed ID: 7897373
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment.
    Campistol JM; Esforzado N; Martínez J; Roselló L; Veciana L; Modol J; Casellas J; Pons M; de Las Cuevas X; Piera J; Oliva JA; Costa J; Barrera JM; Bruguera M
    Nephrol Dial Transplant; 1999 Nov; 14(11):2704-9. PubMed ID: 10534516
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.
    Suzuki T; Tanaka E; Matsumoto A; Urushihara A; Sodeyama T
    J Med Virol; 1995 Jun; 46(2):162-8. PubMed ID: 7636506
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Appropriate interferon-alpha therapy for chronic hepatitis C: an assessment by quantitative changes in serum hepatitis C virus-RNA.
    Watanabe S; Kobayashi Y; Konishi M; Yokoi M; Kakehashi R; Kaito M; Suzuki S
    Intern Med; 1993 Jul; 32(7):523-9. PubMed ID: 8286827
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.
    El-Zayadi AR; Attia M; Badran HM; El-Tawil A; Zalata K; Barakat E; Selim O; El-Nakeeb A; Saied A
    Liver Int; 2005 Aug; 25(4):746-51. PubMed ID: 15998425
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum levels of soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alpha.
    Morishima I; Kumada T; Nakano S; Takeda I; Sugiyama K; Osada T; Kiriyama S; Ohki H; Suga T; Ito O
    Scand J Gastroenterol; 1995 Aug; 30(8):807-11. PubMed ID: 7481551
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis.
    Zignego AL; Fontana R; Puliti S; Barbagli S; Monti M; Careccia G; Giannelli F; Giannini C; Buzzelli G; Brunetto MR; Bonino F; Gentilini P
    J Med Virol; 1997 Apr; 51(4):313-8. PubMed ID: 9093946
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon alpha 2b therapy.
    Van Thiel DH; Caraceni P; Molloy PJ; Hassanein T; Kania RJ; Gurakar A; Friedlander L
    J Hepatol; 1995 Nov; 23(5):503-8. PubMed ID: 8583136
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
    Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
    Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C.
    Mahmood S; Yamada G; Niiyama G; Kawanaka M; Togawa K; Sho M; Ito T; Sasagawa T; Okita M; Nakamura H; Yodoi J
    Free Radic Res; 2003 Jul; 37(7):781-5. PubMed ID: 12911275
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.
    Ampurdanés S; Olmedo E; Maluenda MD; Forns X; López-Labrador FX; Costa J; Sánchez-Tapias JM; de Anta MT; Rodés J
    J Hepatol; 1996 Dec; 25(6):827-32. PubMed ID: 9007709
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis.
    Bacq Y; Sentilhes L; Reyes HB; Glantz A; Kondrackiene J; Binder T; Nicastri PL; Locatelli A; Floreani A; Hernandez I; Di Martino V
    Gastroenterology; 2012 Dec; 143(6):1492-501. PubMed ID: 22892336
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intrahepatic cholestasis of pregnancy: observational study of the treatment with low-dose ursodeoxycholic acid.
    Joutsiniemi T; Timonen S; Linden M; Suvitie P; Ekblad U
    BMC Gastroenterol; 2015 Jul; 15():92. PubMed ID: 26215400
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of chronic hepatitis C with amantadine.
    Smith JP
    Dig Dis Sci; 1997 Aug; 42(8):1681-7. PubMed ID: 9286234
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum HCV RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment.
    Weiland O; Zhang YY; Widell A
    Scand J Infect Dis; 1993; 25(1):25-30. PubMed ID: 8384732
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of ursodeoxycholic acid (ursodiol) treatment on chronic viral hepatitis in heart transplant patients: results of a prospective, double-blind, placebo-randomized study.
    Cadranel JF; Di Martino V; Dorent R; Bernard B; Hoang C; Myara A; Pauwels A; Ghoussoub JJ; Perrin M; Grippon P; Thabut D; Trivin F; Huraux JM; Gandjbakhch I; Opolon P; Lunel F
    Transplantation; 2003 Apr; 75(7):977-82. PubMed ID: 12698083
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM.
    Douglas DD; Rakela J; Lin HJ; Hollinger FB; Taswell HF; Czaja AJ; Gross JB; Anderson ML; Parent K; Fleming CR
    Dig Dis Sci; 1993 Apr; 38(4):601-7. PubMed ID: 8384978
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment.
    Ersöz G; Günşar F; Karasu Z; Akay S; Batur Y; Akarca US
    Turk J Gastroenterol; 2005 Sep; 16(3):124-8. PubMed ID: 16245220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.